Endo recalls self-injected male sexual dysfunction drug Edex

Endo Pharmaceuticals has had a string of recalls in the last few years.

Endo is having a hard time. The Dublin-based company, which Tuesday reported a $3.34 billion loss for the fourth quarter, is recalling one lot of an erectile dysfunction drug that is injected directly into the penis because of a problem with containers that could lead to infections.

According to a company release circulated in an FDA Safety Alert, its Endo Pharmaceuticals unit is recalling one lot of Edex because of a defect in the crimp caps. It said the problem could lead to contamination, which in turn could result in infections, not just localized but also systemically. So far, Endo said it has not received any reports of that happening.

The recall applies to the 10 mcg strength, which is packaged in a two-pack carton and was distributed to wholesalers and pharmacies throughout the U.S. from Dec. 13, 2016, through Feb. 13, 2017. It has a lot number of 207386.

Webinar This Week

OTC Innovation to Avoid Stagnation: Survey Insights, Expert Advice, and Latest Technologies to Boost Your Product’s Performance

Join us for a complimentary webinar on November 13 at 11am ET / 8am PT. Listen to industry experts as they analyze the critical role of innovation in OTC products, and strategies for achieving it.

The company has had a string of recalls in the last couple of years. In November, it recalled 162 lots, comprising 1,365,559 tablets, of its Gildess birth control pills because some of them may have been subpotent. Those were made by its Par unit, which the drugmaker acquired in 2015 in an $8 billion deal.

Endo, which has struggled since that deal, reported today that in the fourth quarter, its revenue rose 16% to $1.24 billion but its loss widened to $3.34 billion. Paul Campanelli, who was named CEO last September, said the company is making progress turning the situation around. Among other efforts, he said the company streamlined its global supply chain.

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.